Role of vasodilators in regurgitant valve disease
- 41 Downloads
Vasodilator therapy is designed to reduce regurgitant volume and improve left ventricular function. Acute administration reduces vascular resistance and decreases regurgitant volume and left ventricular filling pressure. These effects may be clinically useful in acute regurgitations, but less consistent results have been reported in long-term therapy. In chronic mitral functional regurgitation, vasodilator therapy has proved to have clinical or prognostic benefit only when heart failure or poor ventricular function is present. The indication of vasodilator treatment in aortic regurgitation has raised significant controversy. Several studies with small series have shown beneficial effects on regurgitant volume, ejection fraction, and mass of the left ventricle. Nevertheless, in the only two randomized long-term follow-up studies, results differed completely. In our experience, both nifedipine and enalapril failed to reduce the need for valvular surgery or show benefits in echocardiographic parameters. Vasodilator therapy would be indicated only in patients with severe aortic regurgitation and systemic hypertension, or when surgery is contraindicated.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 14.Evangelista A, Tornos P, Sambola A, et al.: Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med 2005, 353:1342–1349. This prospective randomized trial of nifedipine, enalapril, and no treatment in chronic, asymptomatic severe AR failed to show that vasodilator had any benefit in reducing the need for surgery or in echocardiographic variables. Patients with moderate-severe hypertension were excluded and blood pressure reduction was not obtained in the patients treated with vasodilators.PubMedCrossRefGoogle Scholar
- 22.Bonow RO, Carabello B, Chatterjee K, et al.: ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardol 2006, 48:e1-e148. These guidelines present a comprehensive review of valvular heart disease, including MR and AR, with detailed discussion of the recommendations for vasodilator therapy in the acute and chronic phases.CrossRefGoogle Scholar
- 35.Nemoto S, Hamawaki M, De Freitas G, Carabello BA: Differential effects of the angiotensin-converting enzyme inhibitor lisinopril versus the beta-adrenergic receptor blocker atenolol on hemodynamics and left ventricular contractile function in experimental mitral regurgitation. J Am Coll Cardiol 2002, 40:149–154.PubMedCrossRefGoogle Scholar
- 36.Scognamiglio R, Negut Ch, Palisi M, et al.: Long-term and functional results after aortic valve replacement in asymptomatic patients with chronic severe aortic regurgitation and left ventricular dysfunction. J Am Coll Cardiol 2005, 45:1025–1030. This controversial study suggests that treatment with nifedipine before surgery has a protective effect after surgery. Nifedipine allows one to indicate surgery with a reduced ejection fraction with low mortality and an optimal long-term outcome. By contrast, patients with reduced ejection fraction and not treated with nifedipine presented irreversible myocardial damage despite prompt surgery.PubMedCrossRefGoogle Scholar